Search for: "Ely Lilly"
Results 1201 - 1220
of 2,157
Sort by Relevance
|
Sort by Date
5 Aug 2011, 9:55 pm
Eli Lilly for compliance and patent challenges. [read post]
4 Aug 2011, 8:27 am
In Eli Lilly & Co. v. [read post]
4 Aug 2011, 1:02 am
[via: Eli Lilly's law department goes into the classroom at InsideCounsel]Advertisement: * Find an In-House Counsel Job @ GoInhouse.com *Like this post? [read post]
3 Aug 2011, 3:31 am
: Cour d’Appel Paris decision in Teva v Eli Lilly (Kluwer Patent Blog) US: CAFC confirms that isolated DNA may be patented: Association for Molecular Pathology v. [read post]
1 Aug 2011, 8:19 am
According to the Indianapolis Business Journal, the drug generated $577 million in sales for Lilly last year.The case is Eli Lilly & Co. v. [read post]
31 Jul 2011, 9:28 pm
"An assortment of medical organizations, researchers, genetic counselors, and patients" filed a declaratory judgment action against 15 claims of seven Myriad patents. [read post]
27 Jul 2011, 1:01 am
KG (TTABlog) US: ALJ Rogers sets 17-month target date in Certain Coenzyme Q10 Products (337-TA-790) (ITC 337 Law Blog) Products Alimta (Pemetrexed) – US: Eli Lilly files patent infringement complaints against APP Pharmaceuticals in Delaware and S D Indiana in response to Para IV certification filing (Patent Docs) Cenestin (Synthetic conjugated estrogens) – US: CAFC: Prosecution history estoppel bars Duramed’s allegations of infringement under doctrine of… [read post]
25 Jul 2011, 1:07 am
will be decided this week, this time by the European Patent Office in Human Genome Sciences Inc v Eli Lilly and Company [2010] EWCA Civ 33. [read post]
24 Jul 2011, 9:44 am
Human Genome Sciences Inc v Eli Lilly and Company, heard 18 – 20 July 2011. [read post]
21 Jul 2011, 1:17 pm
The drug is being developed by Bristol-Myers Squibb and AstraZeneca, and other major manufacturers such as Johnson & Johnson and Eli Lilly are pursing similar drugs. [read post]
20 Jul 2011, 4:04 am
: Supreme Court hearing Human Genome Sciences Inc v Eli Lilly and Company (IPKat) Nexium (Esomeprazole) – UK: EWHC: Ranbaxy wins declaration of non-infringement: Ranbaxy v AstraZeneca (IPKat) Olanzapine – Spain: Supreme Court hands down landmark judgment on doctrine of equivalents and TRIPS (Kluwer Patent Blog) OxyContin (Oxycodone) – US: Purdue files patent infringement suit against Sandoz in response to Para IV certification (Patent Docs) Prevacid (Lansoprazole)… [read post]
19 Jul 2011, 6:03 am
Here's the list for 2011 so far: Potential Signals of Serious Risks/New Safety Information Identified by AERS, January to March 2011 Product Potential Signal of a Serious Risk/New Safety Information Additional Information (as of May 31, 2011) … [read post]
19 Jul 2011, 5:58 am
Eli Lilly & Co. said patients with Alzheimer’s disease whose conditions worsened upon taking the experimental drug semagacestat didn’t improve after dosing was halted. [read post]
19 Jul 2011, 4:39 am
The United Kingdom's Supreme Court is currently hearing the appeal in an important patent case, Human Genome Sciences Inc v Eli Lilly and Company UKSC 2010/0047. [read post]
19 Jul 2011, 1:35 am
In Human Genome Sciences Inc v Eli Lilly and Company [2010] EWCA Civ 33, all of these questions had to be considered before evaluating the validity of a patent owned by Human Genome Sciences (“HGS”). [read post]
17 Jul 2011, 9:55 am
There are two appeals in the Supreme Court beginning with Human Genome Sciences Inc v Eli Lilly and Company to be heard on Monday 18 to Wednesday 20 July 2011 by Lords Hope, Walker, Neuberger, Collins and Clarke. [read post]
15 Jul 2011, 1:15 pm
Indianapolis, IN - Patent lawyers for Eli Lilly Company of Indianapolis, Indiana filed a patent infringement judgment suit in the Southern District of Indiana alleging APP Pharmaceuticals LLC of Schaumburg, Illinois infringed patent no.7,772,209 , Antifolate combination therapies, which has been issued by the US Patent Office. [read post]
14 Jul 2011, 2:00 am
(Eli Lilly & Co. case). [read post]
14 Jul 2011, 2:00 am
(Eli Lilly & Co. case). [read post]
12 Jul 2011, 7:20 am
At Eli Lilly, the company failed in its fifth consecutive effort to receive the requisite more than 80% outstanding shares in support. [read post]
